BioCentury | May 22, 2020
Product Development

May 21 Quick Takes: EC approves Zolgensma for SMA; plus Sunovion, Kadmon, Sorrento, tafasitamab, Zentalis’ new JV

Immediate access to Zolgensma in France  The European Commission conditionally approved Zolgensma onasemnogene abeparvovec from Novartis AG (NYSE:NVS; SIX:NOVN) to treat spinal muscular atrophy in babies and young children who have SMA Type 1 or...
BioCentury | Feb 1, 2020
Translation in Brief

Preclinical Roundup: CureVac gets CEPI funding for 2019 coronavirus; plus blockade of CD47-SIRPA for atherosclerosis, Stanford and IBM-CDHI

CureVac gets CEPI funding for 2019 coronavirus  The Coalition for Epidemic Preparedness Innovations and CureVac AG are extending a February 2019 collaboration to include a vaccine against the 2019-nCoV acute respiratory disease. The company will...
BC Extra | Nov 22, 2019
Preclinical News

Nov. 21 Preclinical Quick Takes: Excision applies CRISPR editing to herpes, John Cunningham viruses; plus Caribou, Oligomerix, Kymab and Gladstone-Boston Univer

Excision targets CRISPR to herpes, JC viruses  Excision BioTherapeutics Inc. and collaborators at Temple University presented a pair of posters at the International Symposium on NeuroVirology meeting in Atlanta showing CRISPR-Cas9 gene editing could treat...
BC Extra | Nov 12, 2019
Clinical News

Early success in GvHD sets up NDA for Kadmon’s lead

With its lead clinical candidate meeting the primary endpoint at an interim analysis of a pivotal trial for third-line chronic graft-versus-host disease, Kadmon plans to submit an NDA next year for KD025 following next half's...
BC Extra | Sep 26, 2019
Preclinical News

Sept. 26 Preclinical Quick Takes: $30M for new lung disease lab; plus AI-derived compounds from Auransa, Atomwise, and diabetes candidates

Bayer, Brigham and Mass General open lung disease-focused lab  Bayer AG (Xetra:BAYN) will invest more than $30 million over five years to fund research into new treatments for chronic lung diseases, such as chronic obstructive...
BC Innovations | Aug 15, 2019
Distillery Therapeutics

TMED9 inhibition for mucin 1 kidney disease

DISEASE CATEGORY: Renal; ophthalmic INDICATION: Renal; retinitis Blocking the vesicular cargo receptor TMED9 could treat mucin 1 kidney disease, a proteinopathy caused by a frameshift mutation in MUC1, and other misfolded protein diseases. The Harvard...
BC Innovations | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BC Extra | Mar 13, 2019
Company News

FDA approves Aerie glaucoma therapy Rocklatan

Aerie said late Tuesday FDA approved Rocklatan netarsudil/latanoprost to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The product is a fixed-dose combination of Aerie's Rhopressa netarsudil 0.02%, a dual inhibitor of...
BC Week In Review | Feb 15, 2019
Clinical News

Redx to test antifibrotic in clinic for NASH in 2020

Redx Pharma plc (LSE:REDX) said its lead Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor reduced collagen deposition in animal models of lung, kidney and liver fibrosis. The company also said the compound has a...
BC Innovations | Dec 5, 2018
Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived placenta-like organoids could be used to study preeclampsia and other pregnancy-related disorders and screen therapies to treat them. The organoids are generated by culturing human placenta-derived trophoblasts in culture media with...
Items per page:
1 - 10 of 356